Recurrent or Refractory B Cell Malignancy
2 clinical trials · Condition
◉ Watch Recurrent or Refractory B Cell Malignancy
| Record | Firm | Date |
|---|---|---|
| Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma (NCT03207178) | Shanghai Longyao Biotechnology Inc., Ltd. | 2017-03-01 |
| CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies (NCT02794961) | Kai Lin Xu; Jun Nian Zheng | 2016-06-01 |
Track Recurrent or Refractory B Cell Malignancy automatically
Every clearance here is in the API, with alerts when new ones post.